(Lung Cancer) Brigatinib Drug Information
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- October 21, 2015
- 1 min read
At the World Conference on Lung Cancer (WCLC) held in the United States from September 6–9, Dr. Scott N. Gettinger of Yale University presented promising data on brigatinib, an ALK inhibitor for non-small cell lung cancer (NSCLC). Of 70 evaluable patients, 50 demonstrated tumor reduction, including 4 with complete tumor resolution.
For detailed study information, please refer to the following links:
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113: https://clinicaltrials.gov/ct2/show/NCT01449461
A Phase 2, Multicenter, Randomized Study of AP26113 (ALTA): https://clinicaltrials.gov/ct2/show/NCT02094573
Lung Cancer
- Discovering the key to aggressive pancreatic cancer!
- New immune enhancers boosting cancer immunotherapy
- Kyoto University launches iPS cell cancer treatment!
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4